A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
An Open-label, Multicenter Study of ZL-1310 as a Single Agent and In Combination with Atezolizumab to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
SCLC
DRUG: ZL-1310|DRUG: Atezolizumab|DRUG: Carboplatin
Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent, Number of subjects with Dose Limiting Toxicities (DLTs), up to 24 months|Incidence of Dose Limiting Toxicities of ZL-1310 in combination with Atezolizumab, Number of subjects with Dose Limiting Toxicities (DLTs), up to 24 months|Incidence of Dose-Limiting Toxicities of ZL-1310 in combination with Atezolizumab and Carboplatin, Number of subjects with Dose Limiting Toxicities (DLTs), up to 24 months|Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent, Number of subjects with treatment-emergent adverse events (TEAEs), up to 24 months|Incidence of Treatment Emergent Adverse-Events of ZL-1310 in combination with Atezolizumab, Number of subjects with treatment-emergent adverse events (TEAEs), up to 24 months|Incidence of Treatment Emergent Adverse Events of ZL-1310 in combination with Atezolizumab and Carboplatin, Number of subjects with treatment-emergent adverse events (TEAEs), up to 24 months|Incidence of Serious Adverse Events of ZL-1310 as a single agent., Number of subjects with serious adverse events (SAEs), up to 24 months|Incidence of Serious Adverse Events of ZL-1310 in combination with Atezolizumab, Number of subjects with serious adverse events (SAEs), up to 24 months|Incidence of Serious Adverse Events of ZL-1310 in combination with Atezolizumab and Cabroplatin, Number of subjects with serious adverse events (SAEs), up to 24 months
ORR per RECIST 1.1 of ZL-1310 as a single agent, Objective Response Rate (ORR) per RECIST 1.1, up to 24 months|ORR per RECIST 1.1 of ZL-1310 in combination with Atezolizumab, Objective Response Rate (ORR) per RECIST 1.1, up to 24 months|ORR per RECIST 1.1 of ZL-1310 in combination with Atezolizumab and Carboplatin, Objective Response Rate (ORR) per RECIST 1.1, up to 24 months|Duration of Response per RECIST 1.1 of ZL-1310 as a single agent, Duration of Response per RECIST 1.1, up to 24 months|Duration of Response per RECIST 1.1 of ZL-1310 in combination with Atezolizumab, Duration of Response per RECIST 1.1, up to 24 months|Duration or Response per RECIST 1.1 of ZL-1310 in combination with Atezolizumab and Carboplatin, Duration of Response per RECIST 1.1, up to 24 months|PFS per RECIST 1.1 of ZL-1310 as a single agent, Progression free survival (PFS) per RECIST 1.1, up to 24 months|PFS per RECIST 1.1 of ZL-1310 in combination with Atezolizumab, Progression free survival (PFS) per RECIST 1.1, up to 24 months|PFS per RECIST 1.1 of ZL-1310 in combination with Atezolizumab and Carboplatin, PFS per RECIST 1.1, up to 24 months|DCR per RECIST 1.1 of ZL-1310 as a single agent, Disease Control Rate (DCR) per RECIST 1.1, up to 24 months|DCR per RECIST 1.1 of ZL-1310 in combination with Atezolizumab, Disease Control Rate (DCR) per RECIST 1.1, up to 24 months|DCR per RECIST 1.1 of ZL-1310 in combination with Atezolizumab and Carboplatin, DCR per RECIST 1.1, up to 24 months|Overall Survival of ZL-1310 as a single agent, Overall Survival (OS), up to 24 months|Overall Survival of ZL-1310 in combination with Atezolizumab, Overall Survival (OS), up to 24 months|Overall Survival of ZL-1310 in combination with Atezolizumab and Carboplatin, Overall Survival (OS), up to 24 months|Pharmacokinetics (PK): Total Antibody of ZL-1310 as a single agent, Total Antibody, up to 24 months|Pharmacokinetics (PK): Total Antibody of ZL-1310 in combination with Atezolizumab, Total Antibody, up to 24 months|Pharmacokinetics (PK): Total Antibody of ZL-1310 in combination with Atezolizumab and Carboplatin, Total Antibody, up to 24 months|Pharmacokinetics (PK): Unconjugated payloads of ZL-1310 as a single agent, Unconjugated payloads, up to 24 months|Pharmacokinetics (PK): Unconjugated payloads of ZL-1310 in combination with Atezolizumab, Unconjugated payloads, up to 24 months|Pharmacokinetics (PK): Unconjugated payloads of ZL-1310 in combination with Atezolizumab and Carboplatin, Uncongugated payloads, up to 24 months
This is an open-label, ascending, multiple-dose, phase 1 study evaluating ZL-1310 as a single agent, in combination with Atezolizumab, and in combination with Atezolizumab and Carboplatin in subjects with extensive SCLC.